These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 14500391

  • 1. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
    Grove JI, Lovering AL, Guise C, Race PR, Wrighton CJ, White SA, Hyde EI, Searle PF.
    Cancer Res; 2003 Sep 01; 63(17):5532-7. PubMed ID: 14500391
    [Abstract] [Full Text] [Related]

  • 2. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
    Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, Hyde EI, Searle PF.
    Biochem Pharmacol; 2010 Jan 15; 79(2):102-11. PubMed ID: 19665450
    [Abstract] [Full Text] [Related]

  • 3. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.
    Race PR, Lovering AL, White SA, Grove JI, Searle PF, Wrighton CW, Hyde EI.
    J Mol Biol; 2007 Apr 27; 368(2):481-92. PubMed ID: 17350040
    [Abstract] [Full Text] [Related]

  • 4. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
    Mitchell DJ, Minchin RF.
    Cancer Gene Ther; 2008 Nov 27; 15(11):758-64. PubMed ID: 18600257
    [Abstract] [Full Text] [Related]

  • 5. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF.
    Biochem Pharmacol; 2010 Mar 01; 79(5):678-87. PubMed ID: 19852945
    [Abstract] [Full Text] [Related]

  • 6. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
    Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF.
    Cancer Gene Ther; 1997 Mar 01; 4(4):229-38. PubMed ID: 9253508
    [Abstract] [Full Text] [Related]

  • 7. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
    Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI.
    Clin Exp Pharmacol Physiol; 2004 Nov 01; 31(11):811-6. PubMed ID: 15566399
    [Abstract] [Full Text] [Related]

  • 8. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
    Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ, Young LS, Searle PF.
    Gene Ther; 2004 Jul 01; 11(14):1126-36. PubMed ID: 15164095
    [Abstract] [Full Text] [Related]

  • 9. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
    Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I, Knox RJ, Plumb JA, Keith WN.
    Oncogene; 2003 Jan 23; 22(3):370-80. PubMed ID: 12545158
    [Abstract] [Full Text] [Related]

  • 10. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
    Guise CP, Grove JI, Hyde EI, Searle PF.
    Gene Ther; 2007 Apr 23; 14(8):690-8. PubMed ID: 17301844
    [Abstract] [Full Text] [Related]

  • 11. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954.
    de Poorter JJ, Tolboom TC, Rabelink MJ, Pieterman E, Hoeben RC, Nelissen RG, Huizinga TW.
    J Gene Med; 2005 Nov 23; 7(11):1421-8. PubMed ID: 15977303
    [Abstract] [Full Text] [Related]

  • 12. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
    Drabek D, Guy J, Craig R, Grosveld F.
    Gene Ther; 1997 Feb 23; 4(2):93-100. PubMed ID: 9081711
    [Abstract] [Full Text] [Related]

  • 13. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
    McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF.
    Gene Ther; 1998 Aug 23; 5(8):1061-9. PubMed ID: 10326029
    [Abstract] [Full Text] [Related]

  • 14. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
    Blackwood L, O'Shaughnessy PJ, Reid SW, Argyle DJ.
    Vet J; 2001 May 23; 161(3):269-79. PubMed ID: 11352484
    [Abstract] [Full Text] [Related]

  • 15. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
    Jarrom D, Jaberipour M, Guise CP, Daff S, White SA, Searle PF, Hyde EI.
    Biochemistry; 2009 Aug 18; 48(32):7665-72. PubMed ID: 19580253
    [Abstract] [Full Text] [Related]

  • 16. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
    Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF.
    Int J Cancer; 2000 Jun 15; 86(6):848-54. PubMed ID: 10842200
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
    Palmer DH, Milner AE, Kerr DJ, Young LS.
    Br J Cancer; 2003 Sep 01; 89(5):944-50. PubMed ID: 12942130
    [Abstract] [Full Text] [Related]

  • 18. Virus-directed enzyme prodrug therapy using CB1954.
    Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ.
    Anticancer Drug Des; 1999 Dec 01; 14(6):461-72. PubMed ID: 10834268
    [Abstract] [Full Text] [Related]

  • 19. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
    Bailey SM, Knox RJ, Hobbs SM, Jenkins TC, Mauger AB, Melton RG, Burke PJ, Connors TA, Hart IR.
    Gene Ther; 1996 Dec 01; 3(12):1143-50. PubMed ID: 8986441
    [Abstract] [Full Text] [Related]

  • 20. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
    Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA, Ferry D, Kerr DJ.
    Clin Cancer Res; 2001 Sep 01; 7(9):2662-8. PubMed ID: 11555577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.